Indications
Rinvoq (upadacitinib) is a prescription medication that is used to treat various conditions related to inflammation, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis.
Rinvoq contains an active ingredient called upadacitinib. Upadacitinib belongs to Janus kinase (JAK) inhibitor that works by blocking certain signals that are thought to cause inflammation.
Upadacitinib is approved for the treatment of moderate to severe eczema (atopic dermatitis) in adults and children aged 12 years and older who have not responded to previous treatment or whose eczema is not adequately controlled by other pills or injections, including biologic medicines, or where the use of other pills or injections is not recommended.
Uses and Dosage
Rinvoq comes in the form of tablets that are taken orally, usually once daily and can be taken with or without a meal as recommended by your doctor. Swallow the medication and drink a glass of water right after. The extended-release tablets should not be chewed, crushed, or divided, as this can release the active ingredients all at once and increase the risk of adverse effects. Avoid food or drink containing grapefruit during treatment with Rinvoq as it may increase the risk of side effects.
The recommended doses of Rinvoq for maintenance treatment is 15 mg once daily, and a dosage of 30 mg once daily may be considered for patients with refractory. However, this should only be done under the guidance of a healthcare professional.
Side Effect
Common Side Effects of Rinvoq (Upadacitinib):
- Cold symptoms such as stuffy nose
- Cough
- Fever
- Nausea
- Sneezing
- Sore throat
Serious Side Effects of Rinvoq (Upadacitinib):
- A hole (perforation) in your digestive tract - fever, severe stomach pain, diarrhea, or changes in bowel habits
- Chest pain or pressure
- Cold sweat
- Drooping on one side of your mouth
- Increased urination, pain or burning when you urinate
- Light-headed feeling
- Lumps in your neck, armpits, or groin
- Nausea
- Pain
- Redness in an arm or a leg
- Signs of hepatitis - loss of appetite, vomiting, stomach pain (upper right side), dark urine, clay-colored stools, and jaundice (yellowing of the skin or eyes)
- Signs of shingles - flu-like symptoms, tingly or painful blistering rash on one side of your body
- Slurred speech
- Sudden shortness of breath
- Swelling
- Unexplained weight loss
- Vomiting
- Weakness on one side of your body
- Wheezing, trouble breathing, or severe or worsening cough
Form and strength
Rinvoq (Upadacitinib) is available in the following forms and strength:
Rinvoq: Tablet
- 15 mg
- 30mg
Caution
- Use caution when taking Rinvoq with other medications that may increase the risk of infections or other side effects.
- Dosages should be reduced in patient groups who are at risk of venous thromboembolism (VTE), cancer, or major cardiovascular problems, where possible.
- Rinvoq should be used with caution in patients receiving chronic immunosuppressive therapy.
- Do not use Rinvoq during pregnancy or breastfeeding, as it may harm the baby. talk to your doctor if you are pregnant or breastfeeding and are considering Rinvoq.
- Avoid food or drink containing grapefruit during treatment with Rinvoq as it may increase the risk of side effects.
- Do not drink alcohol while taking Rinvoq, as it may increase the risk of liver problems.
Frequently Asked Questions (FAQ)
How does Rinvoq work?
Rinvoq works by blocking a specific protein in the body that is responsible for inflammation in the joints. By reducing inflammation, Rinvoq can help improve the symptoms of rheumatoid arthritis.
How is Rinvoq taken?
Rinvoq is taken orally, once a day, with or without food.
Can Rinvoq be taken with other medications?
It is important to talk to your doctor about any medications or supplements you are taking before starting Rinvoq, as they may interact with each other.
How long does it take for Rinvoq to start working?
Rinvoq may start to work within a few weeks, but it could take several months for the full effects to be seen.
Resources
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf
- https://news.abbvie.com/alert-topics/immunology/abbvie-receives-fda-approval-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-treatment-moderate-to-severe-rheumatoid-arthritis.htm
- https://www.drugs.com/rinvoq.html
- https://www.rxabbvie.com/pdf/rinvoq_pi.pdf
REVIEWS